Theranos issues two years of blood test corrections


Theranos has issued corrections for thousands of blood tests and has voided two years’ worth of results from the popular device that helped value the company at $9 billion.

The embattled firm is currently facing several federal probes over the efficacy of its products.

Theranos spokeswoman Brooke Buchanan said Wednesday that no patients suffered harm due to the inaccurate tests. However, numerous doctors have acknowledged receiving new test results in recent weeks.

Buchanan said Theranos informed The Centers for Medicare and Medicaid Services (CMS) of the voided tests and the corrected results.

Blood tests were annulled for the company’s “Edison” devices which were used in 2014 and 2015.

“Excellence in quality and patient safety is our top priority and we’ve taken comprehensive corrective measures to address the issues CMS raised in their observations,” Buchanan said. “As these matters are currently under review, we have no further comment at this time.”

Universal Basic Income For Dummies

Theranos has been under attack since October when a Wall Street Journal report found that Theranos’ Edison devices may have been providing inaccurate results for thousands of customers.

Theranos has said that Edison “is only one of many proprietary devices used as part of Theranos proprietary technologies.” The Wall Street Journal has claimed that the device was the basis for the company’s $9 billion valuation.

Written by John Howard

John Howard

John Howard is the Business Editor at He is an avid watcher of markets, a wallflower of retail, and a fan of disruptive businesses that utilize technology and unique ideas to form brilliant new ways of doing business.